Boutsikou Efimia, Hardavella Georgia, Fili Eleni, Bakiri Aikaterini, Gaitanakis Stylianos, Kote Alexandra, Samitas Konstantinos, Gkiozos Ioannis
Department of Respiratory Medicine and Oncology, "Theageneio" Anti-Cancer Hospital of Thessaloniki, AL. Simeonidi Str., 54639 Thessaloniki, Greece.
4th-9th Department of Respiratory Medicine, "Sotiria" Athens' Chest Diseases Hospital, 152 Mesogeion Av., 11527 Athens, Greece.
Cancers (Basel). 2024 May 23;16(11):1980. doi: 10.3390/cancers16111980.
Lung Cancer Screening (LCS) is an evolving field with variations in its implementation in various countries. There are only scarce data from National LCS programs.
We aim to provide an up-to-date overview of the current evidence regarding the use of biomarkers in LCS.
A multidisciplinary Task Force experts' panel collaborated and conducted a systematic literature search, followed by screening, review and synthesis of available evidence.
Biomarkers in LCS could be used to improve risk stratification in high-risk participants, improve clarification regarding indeterminate lung nodules and avoid overdiagnosis in suspicious lung findings. Currently, there seem to be promising biomarkers (blood/serum/breath) that have been studied in various trials; however, there is still a lack of solid evidence in clinical validation that would pave the way for their integration into LCS programs.
Biomarkers are the next logical step in improving the LCS pathway and its efficiency by playing an adjuvant role in a minimally invasive way. National LCS programs and pilot studies should integrate biomarkers to validate their accuracy in real-life LCS participants.
肺癌筛查（LCS）是一个不断发展的领域，在各个国家的实施情况存在差异。关于国家肺癌筛查项目的数据非常稀少。
我们旨在提供关于肺癌筛查中生物标志物使用的最新证据综述。
一个多学科的特别工作组专家小组合作进行了系统的文献检索，随后对现有证据进行筛选、审查和综合。
肺癌筛查中的生物标志物可用于改善高危参与者的风险分层，明确不确定的肺结节，并避免可疑肺部检查结果中的过度诊断。目前，在各种试验中似乎已经研究了一些有前景的生物标志物（血液/血清/呼气）；然而，在临床验证方面仍然缺乏确凿的证据，这将为其纳入肺癌筛查项目铺平道路。
生物标志物是以微创方式发挥辅助作用来改善肺癌筛查途径及其效率的下一个合理步骤。国家肺癌筛查项目和试点研究应纳入生物标志物，以验证其在实际肺癌筛查参与者中的准确性。
